These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 10636157

  • 1. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K.
    Neurology; 2000 Jan 11; 54(1):233-5. PubMed ID: 10636157
    [Abstract] [Full Text] [Related]

  • 2. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.
    J Clin Psychiatry; 2006 Sep 11; 67(9):1354-61. PubMed ID: 17017821
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1998 Mar 11; 50(3):645-51. PubMed ID: 9521250
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD.
    J Clin Psychiatry; 2003 Feb 11; 64(2):208-14. PubMed ID: 12633131
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Roesler R, Quevedo J, Walz R, Bianchin M.
    Neurology; 1999 Jun 10; 52(9):1920-1. PubMed ID: 10371554
    [No Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Di Rocco A.
    Neurology; 1999 Jun 10; 52(9):1920; author reply 1920-1. PubMed ID: 10371553
    [No Abstract] [Full Text] [Related]

  • 7. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA, Amsterdam JD.
    Am J Psychiatry; 2002 Nov 10; 159(11):1869-75. PubMed ID: 12411221
    [Abstract] [Full Text] [Related]

  • 8. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD, Bodkin JA.
    J Clin Psychopharmacol; 2006 Dec 10; 26(6):579-86. PubMed ID: 17110814
    [Abstract] [Full Text] [Related]

  • 9. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS, Amsterdam JD.
    J Affect Disord; 2008 Jan 10; 105(1-3):15-23. PubMed ID: 17568687
    [Abstract] [Full Text] [Related]

  • 10. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
    Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F, Collins J, Jones K, Boardman K, Sather M.
    Drug Alcohol Depend; 2006 Dec 01; 85(3):191-7. PubMed ID: 16730924
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.
    Weinberger AH, Reutenauer EL, Jatlow PI, O'Malley SS, Potenza MN, George TP.
    Drug Alcohol Depend; 2010 Mar 01; 107(2-3):188-95. PubMed ID: 19939587
    [Abstract] [Full Text] [Related]

  • 12. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090.
    Evans SR, Yeh TM, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Schifitto G, AIDS Clinical Trials Group and the Neurologic AIDS Research Consortium.
    HIV Clin Trials; 2007 Mar 01; 8(6):437-46. PubMed ID: 18042509
    [Abstract] [Full Text] [Related]

  • 13. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
    Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD.
    J Clin Psychiatry; 2007 Dec 01; 68(12):1860-6. PubMed ID: 18162016
    [Abstract] [Full Text] [Related]

  • 14. Selegiline transdermal system Somerset.
    Mahmood I.
    Curr Opin Investig Drugs; 2002 Aug 01; 3(8):1230-3. PubMed ID: 12211421
    [Abstract] [Full Text] [Related]

  • 15. Transdermal selegiline in patients receiving electroconvulsive therapy.
    Horn PJ, Reti I, Jayaram G.
    Psychosomatics; 2010 Aug 01; 51(2):176-8. PubMed ID: 20332294
    [Abstract] [Full Text] [Related]

  • 16. Selegiline transdermal system: in the treatment of major depressive disorder.
    Frampton JE, Plosker GL.
    Drugs; 2007 Aug 01; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
    [Abstract] [Full Text] [Related]

  • 17. Transdermal selegiline: a novel MAOI formulation for depression.
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2006 Jul 01; 44(7):9-12. PubMed ID: 17310829
    [No Abstract] [Full Text] [Related]

  • 18. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M.
    Issues Ment Health Nurs; 2007 Feb 01; 28(2):223-8. PubMed ID: 17365170
    [No Abstract] [Full Text] [Related]

  • 19. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME.
    J Clin Psychiatry; 2006 Apr 01; 67(4):671-2. PubMed ID: 16669733
    [No Abstract] [Full Text] [Related]

  • 20. [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
    Bettini R, Gorini M.
    Clin Ter; 2002 Apr 01; 153(6):377-80. PubMed ID: 12645393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.